The FDA should be our toughest regulatory body, but the pharmaceutical lobby has torn it to shreds
Natalie Shure writes: Last week the Food and Drug Administration approved Aduhelm—the first new Alzheimer’s drug in 18 years—an event that, at first blush, heralds the amazing news of a medical advance. Perhaps it might have been, had the whole process leading up to the agency giving its nod to the medication played out in a functional health care system. But that’s not what happened. Far from hailing the advent of a transformative breakthrough for the six million Americans suffering…